Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for unresectable ovarian cancer
ChiCTR1900026893Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Probability and severity of adverse reactions and R0 resection rate. Started Oct 2019; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR1900026893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026893.